
Concept Life Sciences
Concept Life Sciences
4 Projects, page 1 of 1
assignment_turned_in Project2019 - 2028Partners:Heptares Therapeutics Limited, GSK (Global), GlaxoSmithKline PLC, Eli Lilly and Company Limited, Chemspeed Technologies AG +44 partnersHeptares Therapeutics Limited,GSK (Global),GlaxoSmithKline PLC,Eli Lilly and Company Limited,Chemspeed Technologies AG,Concept Life Sciences,Dr. Reddy's Laboratories (India),Concept Life Sciences,SK Biotek Ireland,UCB UK,J-Konsult ltd,AstraZeneca plc,Dr Reddy's Laboratories UK Ltd,Merck Serono,Astex,Dr. Reddy's Laboratories (United Kingdom),GSK,Bayer AG,Tocris Bioscience,Ziylo,Ziylo,University of Bristol,Concept Life Sciences (United Kingdom),Merck Sharpe and Dohme Ltd (MSD),Eli Lilly (United States),Eli Lilly (Ireland),GSK (Global),Astex,UCB Celltech (UCB Pharma S.A.) UK,Syngenta Ltd,Bayer AG,J-Konsult ltd,Charles River Laboratories,UCB Pharma (United Kingdom),Heptares Therapeutics,Merck KGaA,ASTRAZENECA UK LIMITED,Charles River Laboratories,Astrazeneca,University of Bristol,Chemspeed Technologies AG,Eli Lilly S.A. - Irish Branch,Eli Lilly and Company Limited,Syngenta Ltd,Tocris Bioscience,Merck Sharpe and Dohme Ltd (MSD),SK Biotek Ireland,Merck (Germany),GlaxoSmithKline (Harlow)Funder: UK Research and Innovation Project Code: EP/S024107/1Funder Contribution: 6,882,770 GBPSynthesis, the science of making molecules, is central to human wellbeing through its ability to produce new molecules for use as medicines and materials. Every new drug, whether an antibiotic or a cancer treatment, is based on a molecular structure designed and built using the techniques of synthesis. Synthesis is a complex activity, in which bonds between atoms are formed in a carefully choreographed way, and training to a doctoral level is needed to produce scientists with this expertise. Our proposed CDT is tailored towards training the highly creative, technologically skilled scientists essential to the pharmaceutical, biotech, agrochemical and materials sectors, and to many related areas of science which depend on novel molecules. Irrespective of the ingenuity of the synthetic chemist, synthesis is often the limiting step in the development of a new product or the advance of new molecular science. This hurdle has been overcome in some areas by automation (e.g. peptides and DNA), but the operational complexity of a typical synthetic route in, say, medicinal chemistry has hampered the wider use of the technology. Recent developments in the fields of automation, machine learning (ML), virtual reality (VR) and artificial intelligence (AI) now make possible a fundamental change in the way molecules are designed and made, and we propose in this CDT to engineer a revolution in the way that newly trained researchers approach synthetic chemistry, creating a new generation of pioneering innovators. Making use of Bristol's extensive array of automated synthetic equipment, flow reactors, peptide synthesisers, and ML Retrosynthesis Tool, students will learn and appreciate this cutting-edge technology-driven program, its potential and its limitations. Bristol has outstanding facilities, equipment and expertise to deliver this training. At its core will be a state-of-the-art research experience in our world-leading research groups, which will form the majority of the 4-year CDT training period. For the 8 months prior to choosing their project, students with complete a unique, multifaceted Technology & Automation Training Experience (TATE). They will gain hands-on experience in advanced techniques in synthesis, automation, modelling and virtual reality. In conjunction with our Dynamic Laboratory Manual (DLM), the students will also expand their experience and confidence with interactive, virtual versions of essential experimental techniques, using simulations, videos, tutorials and quizzes to allow them to learn from mistakes quickly, effectively and safely before entering the lab. In parallel, they will develop their teamworking, leadership and thinking skills through brainstorming and problemsolving sessions, some of them led by our industrial partners. Brainstorming involves the students generating ideas on outline proposals which they then present to the project leaders in a lively and engaging interactive feedback session, which invariably sees new and student-driven ideas emerge. By allowing students to become fully engaged with the projects and staff, brainstorming ensures that students take ownership of a PhD proposal from the start and develop early on a creative and collaborative atmosphere towards problem solving. TATE also provides a formal assessment mechanism, allow the students to make a fully informed choice of PhD project, and engages them in the use of the key innovative techniques of automation, machine learning and virtual reality that they will build on during their projects. We will integrate into our CDT direct interaction and training from entrepreneurs who themselves have taken scientific ideas from the lab into the market. By combining our expertise in synthesis training with new training platforms in automation, ML/AI/VR and entrepreneurship this new CDT will produce graduates better able to navigate the fast-changing chemical landscape.
more_vert assignment_turned_in Project2019 - 2027Partners:European Synch Radiation Facility - ESRF, Helmholtz Association, Centre for Process Innovation (Dup'e), NanoTemper, Reprocell-Europe +47 partnersEuropean Synch Radiation Facility - ESRF,Helmholtz Association,Centre for Process Innovation (Dup'e),NanoTemper,Reprocell-Europe,Astex,Concept Life Sciences (United Kingdom),Max iv,Cambridge Crystallographic Data Centre,South Tees Hospitals NHS Foundtn Trust,Reprocell-Europe,NanoTemper,Universidade de Sao Paulo,CRB,Bruker Daltonik GmbH,Bionow Ltd,CPI Ltd,Newcastle University,LightOx Ltd,Bruker Daltonik GmbH,European Synch Radiation Facility - ESRF,Boehringer Ingelheim Pharma,Newcastle University,Diamond Light Source,High Force Research Ltd,Bionow Ltd,South Tees Hospitals NHS Foundtn Trust,University of Sao Paolo,Diamond Light Source,University of Sao Paulo,GlaxoSmithKline (Harlow),Cambridge Research Biochemicals,High Force Research Ltd,Centre for Process Innovation,Darlington,Max iv,LightOx Ltd,Helmholtz Association of German Research Centres,Arc Trinova Ltd (Arcinova),ALMAC SCIENCES,Glythera Ltd,GlaxoSmithKline PLC,Lund University,Boehringer Ingelheim (International),Concept Life Sciences,Arcinova,Boehringer Ingelheim Pharma,Concept Life Sciences,Almac Group Ltd,CCDC,GSK,Astex,GlytheraFunder: UK Research and Innovation Project Code: EP/S022791/1Funder Contribution: 7,571,970 GBPMolecular sciences, such as chemistry, biophysics, molecular biology and protein science, are vital to innovations in medicine and the discovery of new medicines and diagnostics. As well as making a crucial contribution to health and society, industries in this field provide an essential component to the economy and contribute hugely to employment figures, currently generating nearly 500,000 jobs nationally. To enable and facilitate future economic growth in this area, the CDT will provide a cohort of researchers who have training in both aspects of this interface who will be equipped to become the future innovators and leaders in their field. All projects will be based in both molecular and medical sciences and will focus on unmet medical needs, such as understanding of disease biology, identification of new therapeutic targets, and new approaches to discovery and development of novel therapies. Specific problems will be identified by researchers within the CDT, industrial partners, stakeholders and the CDT students. The research will be structured around three theme areas: Biology of Disease, Molecule and Assay Design and Structural Biology and Computation. The CDT brings together leading researchers with a proven track record across these areas and who have pioneered recent advances in the field, such as multiple approved cancer treatments. Their combined expertise will provide supervision and mentorship to the student cohort who will work on projects that span these research themes and bring their contributions to bear on the medical problems in question. The student cohort approach will allow teams of researchers to work together on joint projects with common goals. Projects will be proposed between academics, industrial partners and students with priority given to those with industrial relevance. The programme of research and training across the disciplines will equip graduates of the CDT with an unprecedented background of knowledge and skills across the disciplines. The programme of research and training across the disciplines will be supplemented by training and hands-on experiences of entrepreneurship, responsible innovation and project management. Taken together this will make graduates of the CDT highly desirable to employers, equip them with the skills they need to envisage and implement future innovations in the area and allow them to become the leaders of tomorrow. A structured and highly experienced management group, consisting of a director, co-directors, theme leads and training coordinators will oversee the execution of the CDT with the full involvement of industry partners and students. This will ensure delivery of the cohort training programme and joint events as well as being accountable for the process of selection of projects and student recruitment. The management team has an established track record of delivery of research and training in the field across industry and academia as well as scientific leadership and network training coordination. The CDT will be delivered as a single, fully integrated programme between Newcastle and Durham Universities, bringing together highly complementary skills and backgrounds from the two institutions. The seamless delivery of the programme across the two institutions is enabled by their unique connectivity with efficient transport links and established regional networks. The concept and structure of the CDT has been developed in conjunction with the industrial partners across the pharmaceutical, biotech and contract research industries, who have given vital steer on the desirability and training need for a CDT in this area as well as to the nature of the theme areas and focus of research. EPSRC funding for the CDT will be supplemented by substantial contributions from both Universities with resources and studentship funding and from industry partners who will provide training, in kind contribution and placements as well as additional studentships.
more_vert assignment_turned_in Project2019 - 2023Partners:ASTRAZENECA UK LIMITED, Sterling Pharma Solutions Ltd., Astrazeneca, Concept Life Sciences, Asynt +11 partnersASTRAZENECA UK LIMITED,Sterling Pharma Solutions Ltd.,Astrazeneca,Concept Life Sciences,Asynt,Concept Life Sciences,University of Leeds,Dr Reddy's Laboratories UK Ltd,Dr. Reddy's Laboratories (United Kingdom),Concept Life Sciences (United Kingdom),University of Leeds,Dr. Reddy's Laboratories (India),Asynt,Imperial College London,Sterling Pharma Solutions Ltd.,AstraZeneca plcFunder: UK Research and Innovation Project Code: EP/S013768/1Funder Contribution: 871,781 GBPThis project aims to deliver the underpinning tools and design principles to support the use of water as a reaction media in High Value Chemical Manufacture. Water has long been promoted as an environmentally friendly and safe 'green' reaction media for synthetic processes which can lead to much more sustainable and cost effective manufacturing process. Nevertheless, the green credential of water has been limited due to issues related to organic contamination of the water waste stream, cost of subsequent treatment and the often required organic solvents at purification stage. Water-accelerated reactions, i.e. reactions which proceed faster in water than in organic solvents and wherein organic reactants and products form hydrophobic droplets, are potential game-changers High Value Chemical Manufacture. They benefit from accelerated rates, improved productivity and much improved green metrics through reduction in the use of organic solvents. Their current limitations are: (i) a limited pool of known reactions; (ii) lack of suitable equipment and process understanding; and (iii) insufficient understanding of acceleration effects which can guide discovery and process design. This project will address these knowledge gaps and deliver the following critical outputs, identified through discussion with our industrial partners in chemical industry sector: (i) a wider range of synthetically useful water-accelerated reactions, (ii) multi-scale batch and flow reactors to support the scale-up pathway for water-accelerated processes, (iii) standardised protocols for characterising such processes and basic process understanding for scaling up, and (iv) streamlined workup/product purification and recycling of water to truly deliver green processes. These outputs will have transformative impacts in the chemical manufacture industry, delivering lower cost and better quality controlled processes through shorter routes, reduced organic waste and facile interfacing between chemo- and biocatalytic processes.
more_vert assignment_turned_in Project2019 - 2027Partners:Concept Life Sciences (United Kingdom), Sygnature Chemical Services Ltd, Bayer Pharma AG, GlaxoSmithKline PLC, Biocleave Limited +18 partnersConcept Life Sciences (United Kingdom),Sygnature Chemical Services Ltd,Bayer Pharma AG,GlaxoSmithKline PLC,Biocleave Limited,Sygnature Chemical Services Ltd,Sumitomo Chemical Group,CRODA INTERNATIONAL PLC,Bayer AG,Green Biologics (United Kingdom),GlaxoSmithKline (Harlow),University of Salford,Arc Trinova Ltd (Arcinova),Arcinova,Astrazeneca,AstraZeneca plc,InnoSyn,Croda (United Kingdom),University of Manchester,CoEBio3,Concept Life Sciences,CoEBio3,InnoSynFunder: UK Research and Innovation Project Code: EP/S023755/1Funder Contribution: 5,972,020 GBPThe EPSRC CDT in Integrated Catalysis (iCAT) will train students in process-engineering, chemical catalysis, and biological catalysis, connecting these disciplines in a way that will transform the way molecules are made. Traditionally, PhD students are trained in either chemocatalysis (using chemical catalysts such as metal salts) or biocatalysis (using enzymes), but very rarely both, a situation that is no longer tenable given the demands of industry to rapidly produce new products based on chemical synthesis. Graduate engineers and scientists entering the chemical industry now need to have the skills and agility to work across a far broader base of catalysis - iCAT will meet this challenge by training the next generation of interdisciplinary scientists and engineers who are comfortable working in both bio and chemo catalysis regimes, and can exploit their synergies for the discovery and production of molecules essential to society. iCAT features world-leading chemistry and engineering groups advancing the state-of-the-art in bio and chemo catalysis, with an outstanding track record in PhD training. The CDT will be managed by a strong and experienced team with guidance from a distinguished membership of an International Advisory Group. The rich portfolio of interdisciplinary CDT projects will feature blue-sky research blended in with more problem-solving studies across scientific themes such as supramolecular-assisted catalysis using molecular machines, directed evolution and biosynthetic engineering for synthesis, and process integration of chemo and bio-catalysis for sustainable synthesis. The iCAT training structure has been co-developed with industry end-users to create a state-of-the-art training centre at the University of Manchester, equipping PhD students with the skills and industrial experience needed to develop new catalytic processes that meet the stringent standards of a future sustainable chemicals industry in the UK. This chemical industry is world-class and a crucial industrial sector for the UK, providing significant numbers of jobs and creating wealth (currently contributing £15 billion of added value each year to our economy). The industry relies first and foremost on skilled researchers with the ability to design and build, using catalysis, molecules with well-defined properties to produce the drugs, agrochemicals, polymers, speciality chemicals of the future. iCAT will deliver this new breed of scientist / engineer that the UK requires, involving industry in the design and provision of training, and dovetailing with other EPSRC-, University-, and Industry-led initiatives in the research landscape.
more_vert